HRMY has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
HRMY has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Pretax income is the income that a company earns before paying income taxes. Harmony Biosciences Holdings's pretax income for the three months ended in Mar. 2024 was $51.8 Mil. Its pretax income for the trailing twelve months (TTM) ended in Mar. 2024 was $187.4 Mil. Harmony Biosciences Holdings's pretax margin was 33.49%.
During the past 6 years, Harmony Biosciences Holdings's highest Pretax Margin was 30.35%. The lowest was -2535.06%. And the median was 12.25%.
The historical data trend for Harmony Biosciences Holdings's Pre-Tax Income can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Harmony Biosciences Holdings Annual Data | |||||||||||||||
Trend | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||
Pre-Tax Income | Get a 7-Day Free Trial | -151.98 | -36.94 | 37.43 | 104.69 | 173.40 |
Harmony Biosciences Holdings Quarterly Data | ||||||||||||||||||||
Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | |
Pre-Tax Income | Get a 7-Day Free Trial | 37.78 | 44.10 | 51.83 | 39.69 | 51.79 |
For the Biotechnology subindustry, Harmony Biosciences Holdings's Pre-Tax Income, along with its competitors' market caps and Pre-Tax Income data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Harmony Biosciences Holdings's Pre-Tax Income distribution charts can be found below:
* The bar in red indicates where Harmony Biosciences Holdings's Pre-Tax Income falls into.
This is the income that a company earns before paying income taxes.
Harmony Biosciences Holdings's Pretax Income for the fiscal year that ended in Dec. 2023 is calculated as
Pretax Income | = | Operating Income | + | Non Operating Income | + | Interest Expense | + | Interest Income | + | Other |
= | 192.03 | + | -9.607 | + | -23.757 | + | 14.73 | + | 0 | |
= | 173.4 |
Harmony Biosciences Holdings's Pretax Income for the quarter that ended in Mar. 2024 is calculated as
Pretax Income | = | Operating Income | + | Non Operating Income | + | Interest Expense | + | Interest Income | + | Other |
= | 52.033 | + | -0.141 | + | -4.535 | + | 4.428 | + | -7.105427357601E-15 | |
= | 51.8 |
Pre-Tax Income for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $187.4 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Harmony Biosciences Holdings (NAS:HRMY) Pre-Tax Income Explanation
Harmony Biosciences Holdings's Pretax Margin for the quarter that ended in Mar. 2024 is calculated as
Pretax Margin | = | Pretax Income | / | Revenue |
= | 51.785 | / | 154.615 | |
= | 33.49% |
During the past 6 years, Harmony Biosciences Holdings's highest Pretax Margin was 30.35%. The lowest was -2535.06%. And the median was 12.25%.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Thank you for viewing the detailed overview of Harmony Biosciences Holdings's Pre-Tax Income provided by GuruFocus.com. Please click on the following links to see related term pages.
Peter Anastasiou | director | C/O HARMONY BIOSCIENCES HOLDINGS, INC., 630 W. GERMANTOWN PIKE, SUITE 215, PLYMOUTH MEETING PA 19462 |
Jack Nielsen | director | C/O AKEBIA THERAPEUTICS, INC., 245 FIRST STREET, SUITE 1100, CAMBRIDGE MA 02142 |
Andreas Wicki | director | C/O HBM BIOVENTURES (CAYMAN) LTD., CENTENNIAL TOWERS,STE.305,2454 W.BAY RD., GRAND CAYMAN E9 E9 |
Andrew Serafin | officer: Chief Business Officer | 630 W. GERMANTOWN PIKE, PLYMOUTH MEETING PA 19462 |
Jeffrey M. Dayno | officer: Chief Medical Officer | 460 EAST SWEDESFORD ROAD, SUITE 1050, WAYNE PA 19087 |
Jeffrey Dierks | officer: Chief Commercial Officer | 630 W. GERMANTOWN PIKE, SUITE 215, PLYMOUTH MEETING PA 19462 |
John C Jacobs | director, officer: President, CEO | 630 W. GERMANTOWN PIKE, SUITE 215, PLYMOUTH MEETING PA 19462 |
Linda M Szyper | director | C/O NEOS THERAPEUTICS, INC., 2940 N. HIGHWAY 250, SUITE 400, GRAND PRAIRIE TX 75050 |
Sandip Kapadia | officer: Chief Financial Officer | 450 WEST 15 STREET, SUITE 505, NEW YORK NY 10011 |
R. Mark Graf | director | C/O DISCOVER FINANCIAL SERVICES, 2500 LAKE COOK ROAD, RIVERWOODS IL 60015 |
Eric L Motley | director | 1516 33RD STREET NW, WASHINGTON DC 20007 |
Valor Equity Partners Iv-a L.p. | 10 percent owner | 875 NORTH MICHIGAN AVENUE, SUITE 3214, CHICAGO IL 60611 |
Valor Equity Partners Iv-b L.p. | 10 percent owner | 875 NORTH MICHIGAN AVENUE, SUITE 3214, CHICAGO IL 60611 |
Marshman Fund Trust Ii | 10 percent owner | 630 W. GERMANTOWN PIKE, SUITE 215, PLYMOUTH MEETING PA 19462 |
Valor Equity Capital Iv Llc | 10 percent owner | 875 N. MICHIGAN AVENUE, SUITE 3214, CHICAGO IL 60611 |
From GuruFocus
By PRNewswire • 10-11-2023
By PRNewswire • 10-13-2023
By PRNewswire • 09-13-2023
By PRNewswire • 09-07-2023
By PRNewswire PRNewswire • 05-10-2023
By PRNewswire • 08-28-2023
By PRNewswire • 10-17-2023
By PRNewswire • 07-20-2023
By PRNewswire PRNewswire • 05-30-2023
By PRNewswire • 08-14-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.